Clinical Trial Update: (SYMPHONY) Phase 1/2 Study Targeting EGFR Resistance Mechanisms in NSCLC [Phase 1]

View source ↗

Summary

The SYMPHONY Phase 1/2 trial targeting EGFR resistance mechanisms in non-small cell lung cancer has been terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Snippet

Sponsor: Blueprint Medicines Corporation | Conditions: Lung Neoplasms, Carcinoma, Non-Small-Cell Lung | Phase 1 | Status: TERMINATED